IL-13Rα2 CRISPR/Cas9 KO Plasmid (h): sc-402525
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IL-13Rα2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IL-13Rα2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IL-13Rα2 Antibody (2K8): sc-134363
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-13Rα2 CRISPR/Cas9 KO Plasmid (h) | sc-402525 | 20 µg | $397.00 |
Overview
IL13RA2 encodes interleukin-13 receptor alpha 2 (IL-13Rα2), a high-affinity IL-13–binding receptor that modulates type 2 cytokine signaling at the cell surface. Unlike the signaling IL-13Rα1/IL-4Rα complex that activates JAK/STAT6 transcriptional programs, IL-13Rα2 is often described as a decoy or context-dependent signaling component that influences IL-13 availability, receptor trafficking, and downstream responses linked to inflammation and tissue remodeling. IL-13Rα2 has been associated with pathways regulating extracellular matrix organization, cell migration, and immune microenvironment crosstalk. Altered IL13RA2 expression has been reported in inflammatory conditions and multiple tumor types, making it a useful target for studying cytokine responsiveness and disease-relevant cellular phenotypes in human model systems.
IL-13Rα2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the IL13RA2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the IL13RA2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the IL13RA2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IL-13Rα2 protein expression.
This CRISPR knockout system enables efficient generation of IL13RA2-deficient cell models for investigation of IL-13Rα2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting IL13RA2 exon(s) critical for IL-13Rα2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple IL13RA2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by IL-13Rα2 CRISPR/Cas9 KO Plasmid (h) and IL-13Rα2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the IL13RA2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by IL-13Rα2 HDR Plasmid (h) and IL-13Rα2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by IL13RA2 homology arms to support homology-directed repair at defined IL13RA2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.